Quick answers
- What is Vasopressin used for?
- The FDA-approved label (Vasopressin, HF Acquisition Co LLC, DBA HealthFirst, July 21, 2026) says: “Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Vasopressin have a boxed warning?
- No. None of the 16 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Vasopressin?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Vasopressin been recalled?
- FDA enforcement reports list 3 recalls of products of this medicine; the newest started August 6, 2026 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Vasopressin?
- 13 companies list prescription products of Vasopressin in the FDA NDC Directory, including HF Acquisition Co LLC, DBA HealthFirst, Eugia US LLC and Gland Pharma Limited.
What Vasopressin is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
— FDA label: Vasopressin, HF Acquisition Co LLC, DBA HealthFirst, effective July 21, 2026. Read the full label on DailyMed →
The FDA has 16 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 16 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Injection · Injection, solution · Solution |
|---|---|
| Route | Intravenous |
| Prescription products | 19 in the FDA NDC Directory |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- HF Acquisition Co LLC, DBA HealthFirst2 products
- Eugia US LLC2 products
- Gland Pharma Limited2 products
- American Regent, Inc.2 products
- Fresenius Kabi USA, LLC2 products
- Baxter Healthcare Corporation2 products
- Long Grove Pharmaceuticals, LLC2 products
- Medical Purchasing Solutions, LLC1 product
- Amphastar Pharmaceuticals, Inc.1 product
- Amneal Pharmaceuticals LLC1 product
- ProPharma Distribution1 product
- Civica, Inc.1 product
- Sagent Pharmaceuticals1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA212593 VASOPRESSIN | Am Regent | August 3, 2020 | — |
| NDA217569 VASOPRESSIN IN SODIUM CHLORIDE 0.9% | Baxter Hlthcare Corp | September 29, 2023 | 2, latest February 21, 2025 2025: Labeling · 2024: Manufacturing (CMC) |
| NDA217766 VASOPRESSIN IN SODIUM CHLORIDE 0.9% | Long Grove Pharms | July 11, 2024 | — |
Generic approvals (5)
- ANDA211857Amphastar Pharms Inc · July 18, 2022
- ANDA212944Amneal · August 5, 2022
- ANDA214314Eugia Pharma · August 15, 2022
- ANDA213206Fresenius Kabi USA · May 26, 2023
- ANDA216963Gland · February 9, 2024
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
August 6, 2026 · Class II · Ongoing · D-0811-2026
CGMP Deviations
Vasopressin, in 0.9% Sodium Chloride Injection, 20 units per 100 mL (0.2 units/mL), 100mL Single-Dose Container, Rx only, Sterile, Baxter Healthcare Corporation, Deerfield, IL, 60012 USA, NDC 0338-9640-12. — Baxter Healthcare Corporation
-
August 6, 2026 · Class II · Ongoing · D-0819-2026
CGMP Deviations
Vasopressin, in 0.9% Sodium Chloride Injection, 40 units per 100 mL (0.4 units/mL), 100mL Single-Dose Container, Rx only, Sterile, Baxter Healthcare Corporation, Deerfield, IL, 60015 USA, NDC 0338-9647-12. — Baxter Healthcare Corporation
-
May 13, 2024 · Class II · Terminated · D-0507-2024
Subpotent product in addition to having out-of-specification results for impurities.
Vasopressin Injection, USP, 200 Units per 10 mL (20 Units per mL), 10 mL Multiple-Dose Vial, Rx only, For Intravenous Infusion, American Regent, Inc., Shirley, NY 11967, NDC 0517-1030-01 — American Regent, Inc.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 313578, 2103182, 2399907, 2591428 |
|---|---|
| SPL set ID of the quoted label | 5232a8bc-d7ae-48a5-e063-6294a90a76ca |
| FDA labels (SPL) | 16 |
| FDA applications | NDA212593, NDA217569, NDA217766, 5 ANDA |
| Active ingredients (FDA) | VASOPRESSIN |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Vasopressin, HF Acquisition Co LLC, DBA HealthFirst, effective July 21, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →